Ayala Pharmaceuticals Company Description

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers.

The company’s lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.

Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

Ayala Pharmaceuticals, Inc.

Country	United States
Industry	Biotechnology
Sector	Healthcare
Employees	21
CEO	Kenneth Berlin

Contact Details

Address: 1007 North Orange Street Wilmington, Delaware 19802 United States
Phone	857 444 0553
Website	ayalapharma.com

Stock Details

Ticker Symbol	ADXS
Exchange	OTCMKTS
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	US0076244062
SIC Code	2836

Key Executives

Name	Position
Kenneth A. Berlin J.D.	Chief Executive Officer, President and Director
Irit Klipper-Avni M.A.	Vice President of Human Resources
Dana Gelbaum M.B.A., M.Sc.	GM and Chief Business Officer